Meet The Expert Panel 




Dr Jeremy Rassen  

Dr. Jeremy A. Rassen, MS, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience. He is co-founder, president, and chief science officer at Aetion, a healthcare technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. He leads the Aetion team in their scientific research collaboration with FDA, which uses advanced analytical techniques to answer questions about the use of diagnostics and medications. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. Dr. Rassen frequently speaks and publishes in peer-reviewed publications on how real-world data can be used to measure the safety, effectiveness and value of medications and other treatments.   

Before coming to Harvard, Dr. Rassen worked in Silicon Valley at a variety of technology companies, including Hewlett-Packard and Epiphany, Inc. His focus was on high-performance software for the creation and analysis of large databases.   


Dr Daniel Rayson  

Division Head, Division of Medical Oncology, QEII Health Sciences Center, Halifax NS 

Professor of Medicine, Dalhousie University, Halifax NS 

Journal of Clinical Oncology, Editorial Board Member 

A World Re-knowned Expert in Oncology with >100 Published Articles, Books & Guidelines.  Dr. Daniel Rayson has invaluable experience with 52 Clinical Trials as Principal Investigator, and served as reviewer for esteemed  publications such as Breast Cancer Research, European Journal of Cancer and Clinical Cancer Research to name but a few. 

Pre-meeting task 

◆    The following materials are provided:

◆    Please read the documents to familiarise yourselves with the palbociclib real-world first-line comparative effectiveness analysis and GRACE assessment, and evaluate/ assess the palbociclib real-world first-line comparative effectiveness analysis according to the provided checklist

PP-PFO-IRL-0032 Date of Preparation October 2021